Adrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Adrian Senderowicz sold 27,000 shares of Puma Biotechnology stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $91,800.00. Following the transaction, the director now directly owns 27,000 shares of the company's stock, valued at approximately $91,800. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Puma Biotechnology Stock Down 6.2%

Shares of Puma Biotechnology stock traded down $0.21 during trading on Friday, hitting $3.19. 314,744 shares of the stock traded hands, compared to its average volume of 443,070. The company has a current ratio of 1.53, a quick ratio of 1.43 and a debt-to-equity ratio of 0.11. The stock's fifty day simple moving average is $3.22 and its 200 day simple moving average is $3.12. The firm has a market cap of $158.32 million, a P/E ratio of 4.14 and a beta of 1.29. Puma Biotechnology, Inc. has a 52-week low of $2.23 and a 52-week high of $4.13.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of PBYI. Bank of New York Mellon Corp boosted its position in shares of Puma Biotechnology by 19.5% in the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company's stock worth $1,012,000 after purchasing an additional 54,150 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Puma Biotechnology by 16.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 285,679 shares of the biopharmaceutical company's stock valued at $871,000 after buying an additional 39,984 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Puma Biotechnology by 32.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 487,368 shares of the biopharmaceutical company's stock worth $1,486,000 after acquiring an additional 118,913 shares in the last quarter. American Century Companies Inc. boosted its holdings in Puma Biotechnology by 8.4% in the fourth quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock worth $2,893,000 after acquiring an additional 73,833 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Puma Biotechnology by 8.0% during the fourth quarter. Sei Investments Co. now owns 311,661 shares of the biopharmaceutical company's stock valued at $951,000 after acquiring an additional 23,179 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PBYI shares. Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.